Literature DB >> 24660049

Statistical approaches to analyzing HIV-1 neutralizing antibody assay data.

Xuesong Yu1, Peter B Gilbert1, Catarina E Hioe2, Susan Zolla-Pazner2, Steven G Self1.   

Abstract

Neutralizing antibody assays are widely used in research toward development of a preventive HIV-1 vaccine. Currently, the neutralization potency of an antibody is typically quantified by the inhibitory concentration (IC) values (e.g., IC50), and the neutralization breadth is estimated by the empirical method. In this paper, we propose the AUC and pAUC measures for summarizing the titration curve, which complement the commonly used IC measure. We present multiple advantages of AUC over IC50, which include no complications due to censoring, the capability to explore low-level neutralization, and improved coverage probabilities and efficiency of estimators. We also propose statistical methods for determining positive neutralization and for estimating the neutralization breadth. The simulation results suggest that the AUC measure is preferable in particular as IC50s get closer to the highest concentration of antibodies tested. For the majority of the assay data, the AUC method is more powerful than the IC50 method. However, since these methods test different hypotheses, it is not unexpected that some virus-antibody combinations are AUC positive but IC50 negative or vice versa.

Entities:  

Keywords:  AUC; HIV-1; breadth; neutralization assay; polynomial model; titration curve

Year:  2012        PMID: 24660049      PMCID: PMC3959164          DOI: 10.1080/19466315.2011.633860

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  15 in total

1.  Statistical significance for genomewide studies.

Authors:  John D Storey; Robert Tibshirani
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-25       Impact factor: 11.205

Review 2.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.

Authors:  Giuseppe Pantaleo; Richard A Koup
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

3.  The five-parameter logistic: a characterization and comparison with the four-parameter logistic.

Authors:  Paul G Gottschalk; John R Dunn
Journal:  Anal Biochem       Date:  2005-08-01       Impact factor: 3.365

4.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

6.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

7.  Resampling-based empirical Bayes multiple testing procedures for controlling generalized tail probability and expected value error rates: focus on the false discovery rate and simulation study.

Authors:  Sandrine Dudoit; Houston N Gilbert; Mark J van der Laan
Journal:  Biom J       Date:  2008-10       Impact factor: 2.207

8.  Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development.

Authors:  Yunda Huang; Peter B Gilbert; David C Montefiori; Steve G Self
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

9.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  International network for comparison of HIV neutralization assays: the NeutNet report.

Authors:  Eva Maria Fenyö; Alan Heath; Stefania Dispinseri; Harvey Holmes; Paolo Lusso; Susan Zolla-Pazner; Helen Donners; Leo Heyndrickx; Jose Alcami; Vera Bongertz; Christian Jassoy; Mauro Malnati; David Montefiori; Christiane Moog; Lynn Morris; Saladin Osmanov; Victoria Polonis; Quentin Sattentau; Hanneke Schuitemaker; Ruengpung Sutthent; Terri Wrin; Gabriella Scarlatti
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

View more
  13 in total

1.  Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities.

Authors:  Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

3.  Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.

Authors:  Benedikt Asbach; Alexander Kliche; Josef Köstler; Beatriz Perdiguero; Mariano Esteban; Bertram L Jacobs; David C Montefiori; Celia C LaBranche; Nicole L Yates; Georgia D Tomaras; Guido Ferrari; Kathryn E Foulds; Mario Roederer; Gary Landucci; Donald N Forthal; Michael S Seaman; Natalie Hawkins; Steven G Self; Alicia Sato; Raphael Gottardo; Sanjay Phogat; James Tartaglia; Susan W Barnett; Brian Burke; Anthony D Cristillo; Deborah E Weiss; Jesse Francis; Lindsey Galmin; Song Ding; Jonathan L Heeney; Giuseppe Pantaleo; Ralf Wagner
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

4.  HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility.

Authors:  Ludy Registre; Yvetane Moreau; Sila Toksoz Ataca; Surya Pulukuri; Timothy J Henrich; Nina Lin; Manish Sagar
Journal:  J Virol       Date:  2020-01-06       Impact factor: 6.549

5.  A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants.

Authors:  Allison S Thomas; Melissa Ghulam-Smith; Alex Olson; Carolyn Coote; Oscar Gonzales; Manish Sagar
Journal:  J Immunol Methods       Date:  2020-03-02       Impact factor: 2.287

6.  Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.

Authors:  S Abigail Smith; Samantha L Burton; William Kilembe; Shabir Lakhi; Etienne Karita; Matt Price; Susan Allen; Eric Hunter; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2016-11-16       Impact factor: 6.823

7.  A single, continuous metric to define tiered serum neutralization potency against HIV.

Authors:  Peter Hraber; Bette Korber; Kshitij Wagh; David Montefiori; Mario Roederer
Journal:  Elife       Date:  2018-01-19       Impact factor: 8.140

8.  Absorbance summation: A novel approach for analyzing high-throughput ELISA data in the absence of a standard.

Authors:  Holly Hartman; Yuge Wang; Harry W Schroeder; Xiangqin Cui
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

9.  Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.

Authors:  Melissa Ghulam-Smith; Alex Olson; Laura F White; Charles S Chasela; Sascha R Ellington; Athena P Kourtis; Denise J Jamieson; Gerald Tegha; Charles M van der Horst; Manish Sagar
Journal:  mBio       Date:  2017-10-24       Impact factor: 7.867

10.  Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays.

Authors:  Shaun S Tan; Sharon Saw; Ka Lip Chew; Chan Yiong Huak; Candy Khoo; Anastacia Pajarillaga; Weixuan Wang; Paul Tambyah; Lizhen Ong; Roland Jureen; Sunil K Sethi
Journal:  Pathology       Date:  2020-09-30       Impact factor: 5.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.